- Editor's PickSeana Smith•3 hours ago
Yahoo Finance is tracking the stocks you’re following, based on your Yahoo Finance ticker searches.
- Editor's PickNicole Sinclair•2 days ago
On Monday, Medivation (MDVN), which owns Xtandi, confirmed it was being acquired by Pfizer (PFE) for $14 billion. This comes just months after Sanofi (SNY) approached Medivation in a hostile deal, going public with its offer and beginning a process to replace the company’s board. Sanofi lost out on its bid to Pfizer, which was willing to pay up and fold Medivation into its oncology franchise.
- Editor's PickSeana Smith•2 days ago
Pfizer is buying Medivation for $14 billion. Medivation’s portfolio includes Xtandi, a treatment for prostate cancer that generates about $2 billion in worldwide annual sales. Valeant Pharmaceuticals (VRX) — Zoetis (ZTS) Chief Financial Officer Paul Herendeen has stepped down to become executive vice president of finance at Valeant and will take over the role of CFO from Robert Rosiello effective immediately.
Pfizer Inc. (PFE)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||35.06 x 3700|
|Ask||35.07 x 8200|
|Day's Range||34.95 - 35.38|
|52wk Range||28.25 - 37.39|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||30.99|
|Avg Vol (3m)||22,247,406|
|Dividend & Yield||1.20 (3.44%)|